Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Pharmacological Research

• Publication date

  2008-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.phrs.2008.09.010PMID 18940259
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression.

  2008cited by this paper
• ABC drug transporter at the blood–brain barrier

  2006cited by this paper
• The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer

  2005cited by this paper
• Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response

  2005cited by this paper
• Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram.

  2005cited by this paper
• Stereoselective Metabolism of Citalopram in Plasma and Cerebrospinal Fluid of Depressive Patients: Relationship with 5-HIAA in CSF and Clinical Response

  2004cited by this paper
• Quinidine as a Probe for the Role of P‐Glycoprotein in the Intestinal Absorption and Clinical Effects of Fentanyl

  2004cited by this paper
• Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance

  2004cited by this paper
• Escitalopram versus citalopram: the surprising role of the R-enantiomer

  2004cited by this paper
• CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene.

  2004cited by this paper
• Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption.

  2003cited by this paper
• abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice.

  2003cited by this paper
• MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients.

  2002cited by this paper
• MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males.

  2002cited by this paper
• Modulation of steady‐state kinetics of digoxin by haplotypes of the P‐glycoprotein MDR1 gene

  2002cited by this paper
• Enantiomers' potential in psychopharmacology--a critical analysis with special emphasis on the antidepressant escitalopram.

  2002cited by this paper
• Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects

  2002cited by this paper
• Identification of functionally variant MDR1 alleles among European Americans and African Americans

  2001cited by this paper
• Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects

  2001cited by this paper
• Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene.

  2001cited by this paper
• Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model.

  2001cited by this paper
• Citalopram therapy for depression: a review of 10 years of European experience and data from U.S. clinical trials.

  2000cited by this paper
• Potential Role of P-Glycoprotein in Affecting Hepatic Metabolism of Drugs

  2000cited by this paper
• Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.

  2000cited by this paper
• Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium.

  1999cited by this paper
• The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs.

  1998cited by this paper
• Analysis of the enantiomers of citalopram and its demethylated metabolites using chiral liquid chromatography.

  1998cited by this paper
• The pharmacological role of P-glycoprotein in the intestinal epithelium.

  1998cited by this paper
• Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.

  1994cited by this paper
• A Monte Carlo method for combined segregation and linkage analysis.

  1992cited by this paper
• Citalopram--pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity.

  1982cited by this paper

• The Effect of ABCB1 Polymorphisms on the Efficacy of Antidepressants

  2025cites this paper
• ABCB1 C1236T, G2677TA and C3435T Genetic Polymorphisms and Antidepressant Response Phenotypes: Results from a Portuguese Major Depressive Disorder Cohort

  2024cites this paper
• Pharmacogenetics and the Blood–Brain Barrier: A Whirlwind Tour of Potential Clinical Utility

  2024cites this paper
• Precision Medicine in Antidepressants Treatment.

  2023cites this paper
• ABCB1 Gene Variants and Antidepressant Treatment Outcomes: A Systematic Review and Meta‐Analysis Including Results from the CAN‐BIND‐1 Study

  2023cites this paper
• Pharmacogenetic Study of the Impact of ABCB1 Single Nucleotide Polymorphisms on the Response to Cyclosporine in Psoriasis Patients

  2022cites this paper
• ABCB1 variants and sex affect serotonin transporter occupancy in the brain

  2022cites this paper
• Predicting Hepatic Clearance of Psychotropic Drugs in Isolated Perfused Fish Livers Using a Combination of Two In Vitro Assays.

  2022cites this paper
• Effects of ABCB1 gene polymorphism on the efficacy of antidepressant drugs

  2021cites this paper
• Influence of eight ABCB1 polymorphisms on antidepressant response in a prospective cohort of treatment‐free Russian patients with moderate or severe depression: An explorative psychopharmacological study with naturalistic design

  2021cites this paper
• The role of pharmacogenetics in the treatment of anxiety disorders and the future potential for targeted therapeutics

  2021cites this paper
• The association between interleukin-8 gene-251 A/T polymorphism and sepsis

  2021cites this paper
• Blood-brain barrier regulation in psychiatric disorders.

  2020cites this paper
• Selected ABCB1 Single Nucleotide Polymorphisms and its Haplotype – Connection with Development of Depression and Treatment Efficacy

  2019cites this paper
• Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug–drug interactions and probability of target attainment

  2019cites this paper
• Pharmacogenomics in Psychiatric Disorders

  2019cites this paper
• Pharmacogenomics and Biomarkers of Depression.

  2019cites this paper
• ABCB1 Gene Is Associated With Clinical Response to SNRIs in a Local Chinese Han Population

  2019cites this paper
• Does G2677T Polymorphism of the MDR1 Gene Make a Difference in the Therapeutic Response to Paroxetine in Depressed Patients in a Slovakian Population?

  2018cites this paper
• Impact of ABCB1 genotype in Collies on the pharmacokinetics of R‐ and S‐fexofenadine

  2018cites this paper
• Neural cell adhesion molecule peptide mimetics modulate emotionality: pharmacokinetic and behavioral studies in rats and non-human primates

  2018cites this paper
• Effect of CYP3 A4, CYP3 A5 and ABCB1 gene polymorphisms on the clinical efficacy of tacrolimus in the treatment of nephrotic syndrome

  2018influential citation
• Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants

  2018cites this paper
• Fine-mapping candidate genes for major depressive disorder: connecting the dots

  2017cites this paper
• Possibility of Predicting Serotonin Transporter Occupancy From the In Vitro Inhibition Constant for Serotonin Transporter, the Clinically Relevant Plasma Concentration of Unbound Drugs, and Their Profiles for Substrates of Transporters.

  2017cites this paper
• Influence of P‐glycoprotein on the disposition of fexofenadine and its enantiomers

  2017cites this paper
• Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks.

  2017cites this paper
• Paving ways for personalizing drug therapy during pregnancy : A focus on the risk of drug teratogenicity

  2017cites this paper
• Quantification of the steady-state plasma concentrations of clozapine and N-desmethylclozapine in Japanese patients with schizophrenia using a novel HPLC method and the effects of CYPs and ABC transporters polymorphisms

  2017cites this paper
• Effect of P-glycoprotein Mediated Inhibition in Drug Bioavailability

  2017cites this paper
• Prenatal exposure to serotonin reuptake inhibitors and congenital heart anomalies: an exploratory pharmacogenetics study.

  2017cites this paper
• One-Year Follow-up of Children and Adolescents with Major Depressive Disorder: Relationship between Clinical Variables and Abcb1 Gene Polymorphisms

  2016cites this paper
• The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors—Is Pharmacogenetics the Key?

  2016cites this paper
• ABCB1 genotyping in the treatment of depression.

  2016cites this paper
• The Effects of Fluvoxamine on the Steady-State Plasma Concentrations of Escitalopram and Desmethylescitalopram in Depressed Japanese Patients

  2016cites this paper
• Measuring citalopram in blood and central nervous system: revealing a distribution pattern that differs from other antidepressants

  2016cites this paper
• P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood-brain barrier in vivo.

  2016cites this paper
• Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study.

  2016influential citation
• Pharmacogenetics and Imaging–Pharmacogenetics of Antidepressant Response: Towards Translational Strategies

  2016cites this paper
• Progress and prospects in pharmacogenetics of antidepressant drugs

  2016cites this paper
• Pharmacogenetics and analgesic effects of antidepressants in chronic pain management.

  2015cites this paper
• Biomarker in der Depressionsbehandlung: mehr als nur Worte? [Biomarkers in clinical depression treatment: more than words?]

  2015cites this paper
• A common polymorphism in the ABCB1 gene is associated with side effects of PGP-dependent antidepressants in a large naturalistic Dutch cohort

  2015cites this paper
• Duloxetine enters the brain - But why is it not found in the cerebrospinal fluid.

  2015cites this paper
• The Influence of C3435T Polymorphism of the ABCB1 Gene on Genetic Susceptibility to Depression and Treatment Response in Polish Population - Preliminary Report

  2015cites this paper
• Pharmacogenetics and Antipsychotic Treatment Response/ Фармакогенетски Тестирања И Одговор Кон Третман Со Антипсихотоци

  2015cites this paper
• ABCB1 gene variants and antidepressant treatment outcome: A meta‐analysis

  2015influential citation
• Association between ABCB1 Polymorphisms and Antidepressant Treatment Response in Taiwanese Major Depressive Patients

  2015cites this paper
• [Characterisation of selected molecular mechanisms influencing pharmacokinetics and pharmacodynamics of antidepressants].

  2015cites this paper
• Species Differences and Impact of Disease State on BBB

  2015cites this paper
• Pharmacogenetics of Major Depressive Disorder: Top Genes and Pathways Toward Clinical Applications

  2015cites this paper
• Identificación de predictores farmacogenéticos en la respuesta terapéutica a Fluoxetina en niños y adolescentes

  2015cites this paper
• ABCB1 (MDR1) predicts remission on P-gp substrates in chronic depression

  2014cites this paper
• Are there meaningful biomarkers of treatment response for depression?

  2014cites this paper
• Understanding the pharmacogenetics of selective serotonin reuptake inhibitors

  2014cites this paper
• Pharmacogenetics of Antidepressant Drugs: An Update

  2014cites this paper
• ABCB1 C3435T polymorphism is associated with susceptibility to major depression, but not with a clinical response to citalopram in a Turkish population

  2014cites this paper
• Markers of Individual Drug Metabolism: Towards the Development of a Personalized Antidepressant Prescription.

  2014cites this paper
• Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients

  2014cites this paper
• Genotype Variability and Haplotype Profile of Abcb1 (Mdr1) Gene Polymorphisms in Macedonian Population

  2014cites this paper
• Effects of escitalopram/quetiapine combination therapy versus escitalopram monotherapy on hypothalamic-pituitary-adrenal-axis activity in relation to antidepressant effectiveness.

  2014cites this paper
• Drugs, genes and the blues: pharmacogenetics of the antidepressant response from mouse to man.

  2014cites this paper
• From Pharmacogenetics to Pharmacogenomics: The Way toward the Personalization of Antidepressant Treatment

  2014cites this paper
• Stereoselectivity of chiral drug transport: a focus on enantiomer–transporter interaction

  2014cites this paper
• Pharmacogenetics in major depression: a comprehensive meta-analysis.

  2013influential citation
• P-glycoprotein inhibition as a strategy to increase drug delivery across the blood-brain barrier: focus on antidepressants

  2013influential citation
• Douleur chronique : rôle de la pharmacogénétique dans la résistance aux antidépresseurs

  2013cites this paper
• Human P-glycoprotein differentially affects antidepressant drug transport: relevance to blood-brain barrier permeability.

  2013cites this paper
• ABCB1 gene polymorphisms are associated with fatal intoxications involving venlafaxine but not citalopram

  2013cites this paper
• Serial CSF sampling over a period of 30 h via an indwelling spinal catheter in healthy volunteers: headache, back pain, tolerability and measured acetylcholine profile

  2013cites this paper
• Pharmacogenetics of antidepressant drugs: An update after almost 20 years of research

  2013cites this paper
• P-glycoprotein (PGP) Polymorphisms and Sexual Dysfunction in Female Patients With Depression and SSRI-Associated Sexual Side Effects

  2013cites this paper
• The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study

  2013cites this paper
• P-glycoprotein Inhibition Increases the Brain Distribution and Antidepressant-Like Activity of Escitalopram in Rodents

  2013cites this paper
• Interactions between antidepressants and P‐glycoprotein at the blood–brain barrier: clinical significance of in vitro and in vivo findings

  2012influential citation
• Association Between Lamotrigine Concentrations and ABCB1 Polymorphisms in Patients With Epilepsy

  2012cites this paper
• Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas.

  2012cites this paper
• Pharmacogenetics of antidepressant drugs: current clinical practice and future directions.

  2012cites this paper
• Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2).

  2012cites this paper
• Clinically Significant Psychotropic Drug-Drug Interactions in the Primary Care Setting

  2012cites this paper
• cabergoline in patients with PRL adenomas

  2012cites this paper
• P-glycoprotein and chiral antidepressant drugs : Pharmacokinetic, pharmacogenetic and toxicological aspects

  2012cites this paper
• Stress-related depression: Neuroendocrine, genetic, and therapeutical aspects

  2012cites this paper
• Predictors of neuropsychiatric side effects of dopamine-agonist therapy in patients with prolactinomas

  2012cites this paper
• Inhibition of P‐glycoprotein enhances transport of imipramine across the blood–brain barrier: microdialysis studies in conscious freely moving rats

  2012cites this paper
• Pharmacogenetics of antidepressant response

  2011cites this paper
• The clinical impact of ABCB1 polymorphisms on the treatment of psychiatric diseases.

  2011cites this paper
• Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition.

  2011cites this paper
• In vitro and In vivo Relevance of the P-glycoprotein Probe Substrates in Drug Discovery and Development: Focus on Rhodamine 123, Digoxin and Talinolol

  2011cites this paper
• Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study

  2011cites this paper
• Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model

  2011cites this paper
• Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein).

  2011cites this paper
• PharmGKB summary: citalopram pharmacokinetics pathway

  2011cites this paper
• Pharmacogenetics of antidepressant response.

  2011cites this paper
• Doxepin concentrations in plasma and cerebrospinal fluid

  2011cites this paper
• Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients.

  2010cites this paper
• Impact of CYP2C19 genetics on pharmacokinetic variability of escitalopram and sertraline : a study based on therapeutic drug monitoring data

  2010cites this paper
• The permeability P-glycoprotein: a focus on enantioselectivity and brain distribution

  2010cites this paper
• Pharmacogenetics of Antidepressants

  2010cites this paper
• Antidepressants and ABCB1 Gene C3435T Functional Polymorphism: A Naturalistic Study

  2010cites this paper